Literature DB >> 23397544

A support vector machine model for predicting non-sentinel lymph node status in patients with sentinel lymph node positive breast cancer.

Xiaowen Ding1, Shangnao Xie, Jie Chen, Wenju Mo, Hongjian Yang.   

Abstract

This study aimed to investigate the accuracy and feasibility of support vector machine (SVM) modeling in predicting non-sentinel lymph node (NSLN) status in patients with SLN-positive breast cancer. Clinicopathological data were collected from 201 cases with sentinel lymph node biopsy breast cancer and included patient age, tumor size, histological type and grade, vascular invasion, estrogen receptor status, progesterone receptor status, CerbB2 status, size and number of positive SLNs, number of negative SLNs, and positive SLN membrane invasion. Feature vector selection was based on a combination of statistical filtration and model-dependent screening. The arbitrary combination with the smallest p value for SVM input was selected, the predicative results of the model were evaluated by a 10-fold cross validation, and a training model was established. Using SLN-positive patients as a double-blind test set, 85 patients were input into the model to analyze its sensitivity and specificity. The combination with the highest cross-validation accuracy was selected for the SVM model and consisted of the following: the number and size of positive SLNs, the number of negative SLNs, and the membrane invasion of positive SLNs. The training accuracy of the model established with the four variables was 92 %, and its cross-validation veracity was 87.6 %. The accuracy of an 85-patient double-blind test of the SVM model was 91.8 %. In conclusion, this SVM model is an accurate and feasible method for the prediction of NSLN status in SLN-positive breast cancer and is conducive to guide clinical treatment.

Entities:  

Mesh:

Year:  2013        PMID: 23397544     DOI: 10.1007/s13277-013-0683-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

1.  Investigation of support vector machines and Raman spectroscopy for lymph node diagnostics.

Authors:  Martina Sattlecker; Conrad Bessant; Jennifer Smith; Nick Stone
Journal:  Analyst       Date:  2010-03-05       Impact factor: 4.616

2.  Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial.

Authors:  Anand David Purushotham; Sara Upponi; Manfred Borislav Klevesath; Lynda Bobrow; Keith Millar; Jonathan Peter Myles; Stephen William Duffy
Journal:  J Clin Oncol       Date:  2005-07-01       Impact factor: 44.544

3.  Metastatic sentinel node and axillary lymphadenectomy revisited.

Authors:  Laia Bernet; Rafael Cano
Journal:  Gland Surg       Date:  2012-05

4.  Sentinel lymph node micrometastases and isolated tumor cells in breast cancer: an evolving field.

Authors:  Fang Fan
Journal:  Gland Surg       Date:  2012-05

5.  Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer.

Authors:  A E Giuliano; P I Haigh; M B Brennan; N M Hansen; M C Kelley; W Ye; E C Glass; R R Turner
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

6.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.

Authors:  Robert E Mansel; Lesley Fallowfield; Mark Kissin; Amit Goyal; Robert G Newcombe; J Michael Dixon; Constantinos Yiangou; Kieran Horgan; Nigel Bundred; Ian Monypenny; David England; Mark Sibbering; Tholkifl I Abdullah; Lester Barr; Utheshtra Chetty; Dudley H Sinnett; Anne Fleissig; Dayalan Clarke; Peter J Ell
Journal:  J Natl Cancer Inst       Date:  2006-05-03       Impact factor: 13.506

7.  Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma.

Authors:  R R Turner; D W Ollila; D L Krasne; A E Giuliano
Journal:  Ann Surg       Date:  1997-09       Impact factor: 12.969

Review 8.  Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.

Authors:  Miraj Shah-Khan; Judy C Boughey
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

9.  Report of incidence and mortality in China cancer registries, 2009.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Guanglin Li; Lingyou Wu; Jie He
Journal:  Chin J Cancer Res       Date:  2013-02       Impact factor: 5.087

10.  Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.

Authors:  Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Gladys L Giron; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.